1.13

5.83% -0.07

After Hours: 1.13

Calidi Biotherapeutics Inc (CLDI)

Overview News Price History Discussions Forecast

Calidi Biotherapeutics Inc stock is traded at $1.13, with a volume of 115.39K. It is down -5.83% in the last 24 hours and down -13.74% over the past month. Calidi Biotherapeutics Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. It engages in advancing a potent allogeneic stem cell capable of carrying an anti-tumor payload for use in multiple oncology indications, including high-grade gliomas and solid tumors. The company's cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Its pipeline of products candidates in the clinic includes NeuroNova that are allogeneic neural stem cells loaded with an oncolytic adenovirus for the treatment of high-grade gliomas; and SuperNova, which are allogeneic adipose-derived mesenchymal stem cells loaded with tumor-selective CAL1 oncolytic vaccinia virus for the treatment of advanced metastatic solid tumors. The company was founded in 2014 and is headquartered in San Diego, California.

Previous Close:

$1.20

Open:

$1.2

24h Volume:

115.39K

Relative Volume:

0.04

Market Cap:

$2.92M

Revenue:

Net Income/Loss:

$-25.09M

P/E Ratio:

-0.218

EPS:

-5.1824

Net Cash Flow:

$-18.40M

1W Performance:

+2.73%

1M Performance:

-13.74%

6M Performance:

+287.38%

1Y Performance:

-22.07%

1-Day Range:

$1.13

$1.2899

1-Week Range:

$1.05

$1.2899

52-Week Range:

$0.095

$1.93

Calidi Biotherapeutics Inc Stock (CLDI) Company Profile

Name

Calidi Biotherapeutics Inc

Sector

Healthcare (1067)

Industry

Biotechnology (595)

Phone

(858) 794-9600

Address

4475 Executive Drive, Suite 200, San Diego

Employee

Twitter

Next Earnings Date

2026-11-12

Latest SEC Filings

CLDI's Discussions on Twitter

Compare CLDI vs VRTX, REGN, MRNA, ARGX, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CLDI Calidi Biotherapeutics Inc	1.13	3.10M	0	-25.09M	-18.40M	-5.1824
VRTX Vertex Pharmaceuticals Inc	526.19	132.40B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	788.04	81.95B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	198.88	77.78B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	959.49	60.20B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	204.97	42.84B	742.00K	-1.37B	-1.07B	-7.0731

Calidi Biotherapeutics Inc Stock (CLDI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-22-23	Initiated	H.C. Wainwright	Buy
Oct-09-23	Initiated	Robert W. Baird	Outperform

Calidi Biotherapeutics Inc Stock (CLDI) Latest News

Sep 25, 2026

Calidi Biotherapeutics Addresses NYSE American Compliance Notice - TipRanks

Sep 25, 2026

Calidi Biotherapeutics Received Notice of Noncompliance - TradingView

Sep 25, 2026

Calidi Biotherapeutics gets NYSE compliance warning but stock surprises - TradingView

Sep 25, 2026

Calidi Biotherapeutics Received NYSE American Notification Letter Regarding Stockholders’ Equity Deficiency - GlobeNewswire

Sep 25, 2026

Sep 22, 2026

Calidi Biotherapeutics Finalizes $1.2M Registered Direct Stock Offering - Kalkine Media

Sep 22, 2026

Calidi Biotherapeutics Announces Registered Direct Stock Offering - TipRanks

Sep 22, 2026

Calidi Biotherapeutics Raises $1.2 Million in Registered Direct Offering at $1.17 Per Share - TradingView

Sep 22, 2026

Sep 17, 2026

Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering - Quiver Quantitative

Sep 17, 2026

Sep 08, 2026

Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewswire

Sep 08, 2026

Sep 01, 2026

Calidi Biotherapeutics Inc. (NYSE: CLDI) Share Price, CLDI Stock News, CLDI Share Price & Updates - Kalkine

Sep 01, 2026

Aug 31, 2026

CLDI Q4 2025 Earnings: Loss Narrows Sharply, Beating Estimates by 73.59%; Shares Rise 3.41%Dividend Earnings Report - vinanet.vn

Aug 31, 2026

Aug 20, 2026

ARMISTICE CAPITAL, LLC Slashes Calidi Biotherapeutics (CLDI) Sta - GuruFocus

Aug 20, 2026

Calidi (CLDI) Quarterly Scorecard: EPS Exceeds Its Estimate in Latest Trading; Market Response: Shares Move Lower 2.90%Dividend Cut Risk - vinanet.vn

Aug 20, 2026

Aug 19, 2026

Calidi Biotherapeutics (CLDI) grants director 5,000 options - Stock Titan

Aug 19, 2026

Calidi director granted 4,000 options at $1.36 | CLDI Insider Trading - Stock Titan

Aug 19, 2026

Calidi Biotherapeutics (CLDI) gives CFO 14,000 options with 10-year term - Stock Titan

Aug 19, 2026

Calidi Biotherapeutics (CLDI) awards director 4,000 options vesting in 1 year - Stock Titan

Aug 19, 2026

Calidi Biotherapeutics (CLDI) CEO awarded 32K options vesting over 4 years - Stock Titan

Aug 19, 2026

Calidi Biotherapeutics (CLDI) grants director 6,000 options vesting in 12 months - stocktitan.net

Aug 19, 2026

Aug 18, 2026

Calidi (CLDI) Report Card: The EPS Result Is Above Expectation in the Current Update; Reaction Snapshot: Shares Close 6.62% Lower in the Latest SessionTrough Earnings Signal - vinanet.vn

Aug 18, 2026

Calidi (CLDI) Closing Snapshot: Retreats 5.59% to $1.28 in the Current Update; Technical Position: the Near-Term Reference Band Stretches From $1.22 to $1.34 on the DayCalendar Spread Trade - vinanet.vn

Aug 18, 2026

Aug 17, 2026

Calidi Biotherapeutics Granted Patent for Cell-Based Oncolytic Virus Immunotherapy for Cancer Treatment - ACCESS Newswire

Aug 17, 2026

Aug 14, 2026

Armistice Capital reports 4.99% Calidi Biotherapeutics (CLDI) stake in Schedule 13G/A - Stock Titan

Aug 14, 2026